Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients – Study of infectious diseases working party of EBMT

Mikulska, Małgorzata; Knelange, Nina; Nicolini, Laura Ambra; Tridello, Gloria; Santarone, Stella; Bartolomeo, Paolo Di; Cámara, Rafael de la; Cuéllar, Clara; Velardi, Andrea; Perruccio, Katia; Ljungman, Per; Zaucha, Jan Maciej; Piekarska, Agnieszka; Basak, Grzegorz W.; Karakulska-Prystupiuk, Ewa; Angelucci, Emanuele; Ciceri, Fabio; Lupo-Stanghellini, Maria Teresa; Fouillard, L; García‐Cadenas, Irene; Menconi, Mariacristina; Blau, Igor Wolfgang; Nassi, Luca; Cesaro, Simone; Styczyński, Jan

doi:10.1016/j.jinf.2021.10.024

Cited by 4 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study we reported the approach to chronic HCV infection and treatment either with IFN or with DAAs. Treatment of chronic HCV infection with DAAs has been recently described in HCT patients [ 37 ]. The main findings in our series are:(1) HCV RNA is undetectable in all 33 patients who received therapy; (2) most patients ( n = 29) show a normal or low grade of liver fibrosis (F0-F1); (3) liver fibrosis was moderate (F2-F3) in 2 patients or advanced (F4) in other 2 patients, although the liver disease in these patients is clinically stable with normal serum biomarkers.…”

Section: Discussionmentioning

confidence: 99%

Survival and late effects of hematopoietic cell transplantation in patients with thalassemia major

Santarone

Angelini

Natale

et al. 2022

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

In this retrospective study, we evaluated long-term survival and late effects in 137 patients affected by thalassemia major (TM) who received an allogeneic hematopoietic cell transplantation (HCT). Median age at HCT was 10.1 years. After a median follow-up of 30 years, 114 (83.2%) patients are living and 108 (78.8%) are cured. The cumulative incidence of nonrelapse mortality and thalassemia recurrence was 9.5% at 1 year and 10.2% at 39 years respectively. The 39-years cumulative incidence of overall survival and disease-free survival were 81.4% and 74.5%. One hundred twenty-three patients who survived more than 2 years after HCT were evaluated for late effects concerning hematological disorders, iron burden, growth, obesity, diabetes mellitus, thyroid and gonadal function, eye, heart, liver, lung, kidney, gastrointestinal, neurologic and psychiatric system, osteoarticular system, secondary solid cancer (SSC), performance status, and Covid-19 infection. Fertility was preserved in 21 males whose partners delivered 34 neonates and 25 females who delivered 26 neonates. Fifteen cases of SSC were diagnosed for a 39-year cumulative incidence of 16.4%. HCT represents a definitive cure for the majority of TM patients at the price, however, of a non-negligible early and late mortality which in the long run affects survival and disease-free survival.

show abstract

Section: Discussionmentioning

confidence: 99%